BSR Intelligence
Daily intelligence on the peptide research industry.
Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.
The week's Intelligence in one email, every Friday morning.
Regulatory moves, trial readouts, supply-chain news. No product pitches. Unsubscribe in one click.
Pharma & GLP-1
argenx Acquires Macrocyclic Peptide Specialist Unnatural Products for Up to $1.15 Billion: What the Deal Signals for Oral Peptide Drug Development
argenx has announced a definitive agreement to acquire Unnatural Products, Inc., a macrocyclic peptide discovery biotech, for $550 million upfront and up to $1.15 billion in total consideration. The deal, announced on 9 November 2026, adds an AI-guided peptide platform to argenx's antibody engineering capabilities and signals growing industry conviction that oral and long-acting peptide medicines represent the next frontier in immunology.
09 Nov 2026
Pharma & GLP-1
Eli Lilly and Hims & Hers Formalise GLP-1 Distribution Partnership: What the Zepbound and Foundayo Agreement Means for the Compounding Market
Eli Lilly announced on 6 November 2026 a formal distribution agreement with Hims & Hers Health, granting the telehealth platform direct access to Zepbound (tirzepatide) and Foundayo (orforglipron) at standardised self-pay prices. A central clause commits Hims & Hers to discontinue compounded copies of Lilly's GLP-1 medicines, reshaping access dynamics for both approved and unapproved peptide products.
06 Nov 2026
Pharma & GLP-1
AstraZeneca's $10 Billion Offer for Rhythm Pharmaceuticals: What a Cyclic Peptide Acquisition Signals for the Obesity Drug Race
AstraZeneca has made a reported non-binding offer of approximately $10 billion to acquire Rhythm Pharmaceuticals, the maker of setmelanotide (Imcivree) — an FDA-approved cyclic octapeptide that targets the melanocortin-4 receptor in rare genetic obesity. The proposed deal, which would be executed through AstraZeneca's rare-disease unit Alexion, positions the British pharma group for a commercial foothold in the fast-growing obesity market and underscores how peptide-based mechanisms are…
05 Nov 2026
Pharma & GLP-1
Gilead Pays $1.275 Billion for an Oral Macrocyclic Peptide: What the PepStar Deal Signals for the Next Wave of Peptide Drug Development
Gilead Sciences agreed on 22 October 2026 to acquire PepStar Therapeutics' oral IL-23R inhibitor programme, led by macrocyclic peptide HCXT-2001, for $1.275 billion upfront. The deal is the latest evidence that big pharma's appetite for oral peptide formats extends well beyond the GLP-1 obesity category into immunology and inflammatory bowel disease.
26 Oct 2026
Pharma & GLP-1
Novo Nordisk Bets €1.165 Billion on Atomic Layer Deposition: What the Nanexa PharmaShell Deal Means for Long-Acting Peptide Formulation
Novo Nordisk has licensed Swedish delivery specialist Nanexa's PharmaShell atomic layer deposition platform for up to five peptide programmes targeting obesity and cardiometabolic disease, with monthly and quarterly dosing as target profiles. The deal, worth up to €1.165 billion, signals that the GLP-1 leaders view reduced injection frequency — not simply new molecules — as a critical next competitive frontier.
24 Oct 2026
Pharma & GLP-1
EMA's CHMP Backs Orforglipron for the EU: What the Non-Peptide GLP-1 Opinion Means for the Research Landscape
The EMA's Committee for Medicinal Products for Human Use issued a positive opinion on 15 October 2026 recommending EU marketing authorisation for Eli Lilly's orforglipron (Foundayo) — a non-peptide, small-molecule GLP-1 receptor agonist. The decision, pending a European Commission rubber-stamp expected within weeks, adds regulatory momentum to a drug that differs structurally from every peptide GLP-1 approved to date, with consequences for manufacturing, compounding policy, and research-supply…
17 Oct 2026
Pharma & GLP-1
Novo Nordisk Bets €1.165 Billion on Atomic-Layer Deposition to Convert Semaglutide Into a Once-Quarterly Injectable
Swedish biotech Nanexa has secured a global exclusive licence from Novo Nordisk worth up to €1.165 billion to apply its PharmaShell atomic-layer deposition platform to peptide programmes in obesity, type 2 diabetes and other cardiometabolic diseases. The deal targets monthly and quarterly dosing profiles, and is backed by preclinical semaglutide data released earlier in 2026.
08 Oct 2026
Pharma & GLP-1
Lilly at EASD 2026: Retatrutide's TRIUMPH-2 Phase 3 Readout, Foundayo's Lancet Cardiovascular Data, and What eloraTZP Signals for the Next Generation of Incretin Combinations
Eli Lilly presented three significant cardiometabolic datasets at the 62nd EASD Annual Meeting in Milan this week. Retatrutide's TRIUMPH-2 Phase 3 trial reported up to 20.8% body-weight reduction in adults with obesity and type 2 diabetes; ACHIEVE-4 Foundayo data, simultaneously published in The Lancet, met cardiovascular non-inferiority versus insulin glargine; and Phase 2 eloraTZP results offered the first clinical look at a tirzepatide-amylin combination. The readouts reinforce Lilly's…
01 Oct 2026
Pharma & GLP-1
Novo Nordisk Licenses Hengrui's Once-Weekly Oral GLP-1/GIP Dual Agonist HRS-1596 in a Deal Worth Up to $2.6 Billion
Novo Nordisk announced on 29 September 2026 that it has licensed HRS-1596, a phase 1-ready oral GLP-1/GIP dual receptor agonist from China's Hengrui Pharma in a deal valued at up to $2.6 billion. The compound carries the potential for once-weekly oral dosing — a frequency not yet achieved by any approved GLP-1 agent — though no human clinical data has been disclosed.
30 Sep 2026
Pharma & GLP-1
CagriSema's FDA Decision Window: What Novo Nordisk's Dual-Peptide Obesity Combination Means for Researchers and UK Access
Novo Nordisk's CagriSema — a fixed-dose combination of semaglutide and cagrilintide — is approaching an FDA decision expected in Q4 2026. As the first injectable amylin–GLP-1 combination to reach the regulatory finish line, its approval or rejection will determine whether dual-peptide combinations become the next standard of care. No MHRA submission has been publicly confirmed, leaving UK availability some way off.
27 Sep 2026
Pharma & GLP-1
Novo Nordisk and Orbis Medicines Sign Up-to-$1.4 Billion Oral Macrocyclic Peptide Pact for Cardiometabolic Disease
Novo Nordisk has entered a discovery and licensing collaboration with Orbis Medicines worth up to $1.4 billion to develop oral macrocyclic peptides for cardiometabolic conditions currently dominated by injectable drugs. The deal, reported by Reuters on 17 September 2026, signals Novo's intent to extend its oral-drug ambitions beyond semaglutide into a structurally distinct molecule class.
18 Sep 2026
Pharma & GLP-1
Lilly's EASD 2026 Disclosures: TRIUMPH-2 Phase 3 Retatrutide Data, ACHIEVE-4 Foundayo Cardiovascular Findings, and a First Look at eloraTZP Phase 2
Eli Lilly published its pre-EASD data package on 15 September 2026, confirming Phase 3 TRIUMPH-2 results for the investigational triple agonist retatrutide, Phase 3 ACHIEVE-4 cardiovascular data for orforglipron (Foundayo), and a forthcoming Phase 2 readout for eloraTZP — a combination of eloralintide and tirzepatide. The disclosures arrive against a backdrop of active illicit-market enforcement, with a regulatory filing for retatrutide expected before year-end.
16 Sep 2026